Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stake Lifted by Finepoint Capital LP

Finepoint Capital LP grew its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 21.3% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 161,935 shares of the biotechnology company’s stock after buying an additional 28,400 shares during the period. Sarepta Therapeutics accounts for approximately 1.2% of Finepoint Capital LP’s portfolio, making the stock its 9th largest position. Finepoint Capital LP owned about 0.17% of Sarepta Therapeutics worth $19,690,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Louisiana State Employees Retirement System raised its stake in Sarepta Therapeutics by 0.4% during the 4th quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company’s stock valued at $3,222,000 after acquiring an additional 100 shares during the last quarter. Manchester Capital Management LLC lifted its holdings in shares of Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 110 shares during the period. UMB Bank n.a. grew its position in Sarepta Therapeutics by 36.0% in the 4th quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company’s stock valued at $63,000 after buying an additional 138 shares during the last quarter. CIBC Asset Management Inc increased its stake in Sarepta Therapeutics by 5.1% in the 4th quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company’s stock valued at $347,000 after buying an additional 139 shares during the period. Finally, PNC Financial Services Group Inc. raised its position in Sarepta Therapeutics by 5.3% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company’s stock worth $352,000 after buying an additional 145 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on SRPT. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a research note on Wednesday, March 19th. HC Wainwright raised Sarepta Therapeutics from a “sell” rating to a “neutral” rating and set a $75.00 target price for the company in a research note on Wednesday. Scotiabank decreased their price target on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating on the stock in a research note on Thursday, March 20th. Royal Bank of Canada cut Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and cut their price objective for the stock from $161.00 to $87.00 in a research report on Monday, March 31st. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $163.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Six equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Sarepta Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $163.18.

Insider Activity

In related news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the transaction, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Down 7.1 %

Shares of NASDAQ SRPT opened at $54.43 on Friday. The firm has a market cap of $5.28 billion, a P/E ratio of 43.54 and a beta of 0.79. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. Sarepta Therapeutics, Inc. has a 1 year low of $54.26 and a 1 year high of $173.25. The firm’s 50 day moving average price is $96.95 and its 200 day moving average price is $113.70.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.